Maquet Cardiopulmonary, a business unit of Maquet Cardiovascular , has executed an agreement to purchase Avalon Laboratories’ Avalon Elite bi-caval dual lumen catheter and complimentary vascular access kits for use during extracorporeal life support (ECLS) procedures.
Approved by the Food and Drug Administration (FDA) and the European Medicines Agency, the Avalon Elite catheter is indicated for simultaneous venous drainage and reinfusion of blood via the internal jugular vein during ECLS procedures.
The catheter is designed to improve the efficiency of blood gas exchange by draining blood from both the upper and lower body, whilst simultaneously re-infusing it directly into the heart.
The Avalon Elite is also used to minimise recirculation and maximise blood flow, while providing a less invasive solution for the patient.
MAQUET Cardiopulmonary president and chief executive officer, Wolfgang Rencken, said the acquisition of the bi-caval dual lumen catheter complements the company’s existing cardiopulmonary product line and strengthens its position as a global provider of ECLS technologies.
"With the addition of the Avalon Elite catheter line, we now offer the customers and patients we serve with a full range of minimally invasive venous or arterial cannulation techniques for ECLS," Rencken added.
"The Avalon Elite bi-caval dual lumen catheter is a state of the art ECLS technology that sets the standard for new Maquet catheter offerings in the future and will play an integral role in new cardiopulmonary offerings from Maquet."
Avalon Laboratories chief executive officer Michael Janish said: "Maquet’s growing leadership in the cardiopulmonary space makes our bi-caval dual lumen catheter the ideal acquisition to further expand the number of patients globally who can benefit from this device."
The Avalon Elite product range will be available via the Maquet global sales and distribution channels, as well as through existing Avalon distributors.